Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2015

Open Access 01-12-2015 | Review

Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence

Authors: Daniele Santini, Luciano Stumbo, Chiara Spoto, Loretta D’Onofrio, Francesco Pantano, Michele Iuliani, Marco fioramonti, Alice Zoccoli, Giulia Ribelli, Vladimir Virzì, Bruno Vincenzi, Giuseppe Tonini

Published in: Breast Cancer Research | Issue 1/2015

Login to get access

Abstract

Bisphosphonates (BPs) are approved as standard therapy in breast cancer for the treatment of bone metastases, since they were demonstrated to reduce the prevalence of skeletal-related events including fractures and hypercalcemia. In the adjuvant setting, BPs can be given to prevent and treat tumor therapy-induced bone loss in premenopausal and postmenopausal women and, owing to their beneficial effect on bone turnover, have also been evaluated for prevention of bone metastases occurrence. In this article we will review the mechanisms through which BPs have been demonstrated to prevent premetastatic niche formation and cell proliferation in bone lesions. Moreover, preclinical evidence of antitumoral effects of BPs will be presented and results from the most important clinical trials will be described critically. BPs may clearly play a clinically important role in early breast cancer in a postmenopausal adjuvant setting.
Literature
1.
2.
Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000;88:2961–78.CrossRefPubMed
3.
Kuo YC, Su CH, Liu CY, Chen TH, Chen CP, Wang HS. Transforming growth factor-beta induces CD44 cleavage that promotes migration of MDA-MB-435s cells through the up-regulation of membrane type 1-matrix metalloproteinase. Int J Cancer. 2009;124:2568–76.CrossRefPubMed
4.
Martínez AS, Huelsken J. The niche under siege: novel targets for metastasis therapy. J Intern Med. 2013;274:127–36.CrossRef
5.
Coleman R, Gnant M, Morgan G, Clezardin P. Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst. 2012;104:1059–67.CrossRefPubMed
6.
Kaplan RN, Psaila B, Lyden D. Bone marrow cells in the “pre-metastatic niche”: within bone and beyond. Cancer Metastasis Rev. 2006;25:521–9.CrossRefPubMed
7.
8.
Luzzi KJ, MacDonald IC, Schmidt EE, et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol. 1998;153:865–73.CrossRefPubMedPubMedCentral
9.
Paget S. The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev. 1989;8:98–101.PubMed
10.
Shiozawa Y, Havens AM, Pienta KJ, Taichman RS. The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia. 2008;22:941–50.CrossRefPubMed
11.
Bidard FC, Vincent-Salomon A, Gomme S, et al. Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse. Clin Cancer Res. 2008;14:3306–11.CrossRefPubMed
12.
Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005;13:793–802.CrossRef
13.
Becker S, Solomayer E, Becker-Pergola G, Wallwiener D, Fehm T. Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients. Breast Cancer Res Treat. 2007;13:239–43.CrossRef
14.
Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res. 2008;14:2519–26.CrossRefPubMed
15.
16.
Lipton A, Chapman JA, Demers L, et al. Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: results of NCIC CTG MA.14. J Clin Oncol. 2011;29:3605–10.CrossRefPubMed
17.
Kraemer B, Rothmund R, Banys M, et al. Impaired bone microenvironment: correlation between bone density and presence of disseminated tumor cells. Anticancer Res. 2011;13:4423–8.
18.
Solomayer EF, Gebauer G, Hirnle P, et al. Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients. Ann Oncol. 2012;23:2271–7.CrossRefPubMed
19.
Hoffmann O, Aktas B, Goldnau C, et al. Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer: a pilot study. Anticancer Res. 2011;31:3623–8.PubMed
20.
Aft R, Naughton M, Trinkaus K, et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol. 2010;11:421–8.CrossRefPubMedPubMedCentral
21.
Lin AY, Park JW, Scott J, Melisko M, Goga A, Moasser M, et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow [Abstract 559]. J Clin Oncol. 2008;13:20s.
22.
Banys M, Solomayer EF, Gebauer G, et al. Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial. BMC Cancer. 2013;13:480.CrossRefPubMedPubMedCentral
23.
Hartkopf AD, Taran FA, Wallwiener M, Hahn M, Becker S, Solomayer EF, et al. Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients—results from a large single-centre analysis. Eur J Cancer. 2014;50:2550–9.CrossRefPubMed
24.
Winter MC, Holen I, Coleman RE. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev. 2008;34:453–75.CrossRefPubMed
25.
Van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Lowik C, Papapoulos S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest. 1996;13:698–705.CrossRef
26.
Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 2000;13:2949–54.
27.
Daubiné F, Le Gall C, Gasser J, et al. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst. 2007;99:322–30.CrossRefPubMed
28.
Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer. 2000;82:1459–68.CrossRefPubMedPubMedCentral
29.
Fournier PG, Stresing V, Ebetino FH, Clezardin P. How do bisphosphonates inhibit bone metastasis in vivo? Neoplasia. 2010;13:571–8.CrossRef
30.
Clézardin P. Bisphosphonates’ antitumor activity: an unravelled side of a multifaceted drug class. Bone. 2011;48:71–9.CrossRefPubMed
31.
Roelofs AJ, Thompson K, Ebetino FH, et al. Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Curr Pharm Des. 2010;16:2950–60.CrossRefPubMed
32.
Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007;449:557–63.CrossRefPubMed
33.
Gallo M, De Luca A, Lamura L, Normanno N. Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer. Ann Oncol. 2012;23:597–604.CrossRefPubMed
34.
Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2002;13:1055–61.CrossRef
35.
Santini D, Vincenzi B, Avvisati G, et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res. 2002;8:1080–4.PubMed
36.
Santini D, Vincenzi B, Dicuonzo G, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res. 2003;9:2893–7.PubMed
37.
Santini D, Vincenzi B, Galluzzo S, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res. 2007;13:4482–6.CrossRefPubMed
38.
Maniar A, Zhang X, Lin W, et al. Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. Blood. 2010;116:1726–33.CrossRefPubMedPubMedCentral
39.
Benzaïd I, Mönkkönen H, Stresing V, et al. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo. Cancer Res. 2011;71:4562–72.CrossRefPubMed
40.
Syddall SP, Ottewell PD, Holen I. Combined therapies of bone disease with bisphosphonates. Curr Pharm Des. 2010;16:2988–97.CrossRefPubMed
41.
Diel IJ, Jaschke A, Solomayer EF, Gollan C, Bastert G, Sohn C, et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow–a long-term follow-up. Ann Oncol. 2008;19:2007–11.CrossRefPubMedPubMedCentral
42.
Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Res. 2006;8:R13.CrossRefPubMedPubMedCentral
43.
Saarto T, Vehmanen L, Virkkunen P, Blomqvist C. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol. 2004;43:650–6.CrossRefPubMed
44.
Paterson AH, Anderson SJ, Lembersky BC, Fehrenbacher L, Falkson CI, King KM, et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol. 2012;13:734–42.CrossRefPubMedPubMedCentral
45.
Brufsky AM, Bosserman LD, Caradonna RR, Haley BB, Jones CM, Moore HC, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer. 2009;9:77–85.CrossRefPubMed
46.
Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol. 2013;24:398–405.CrossRefPubMed
47.
Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med. 2011;365:1396–405.CrossRefPubMed
48.
von Minckwitz G, Rezai M, Eidtmann H, et al. Post-neoadjuvant treatment with zoledronate in patients with tumor residuals after anthracyclines-taxane-based chemotherapy for primary breast cancer–the phase III NATAN study (GBG 36/ABCSG XX). [Abstract S5-05]. San Antonio Breast Cancer Symposium, San Antonio, Texas. Presented 12 Dec 2013.
49.
Coleman R, Gnant M, Paterson A, et al. Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: a meta-analysis of individual patient data from randomized trials [Abstract S4-07]. San Antonio Breast Cancer Symposium, San Antonio, Texas. Presented 12 Dec 2013.
50.
Valachis A, Polyzos NP, Coleman RE, Gnant M, et al. Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. Oncologist. 2013;18:353–61.CrossRefPubMedPubMedCentral
51.
Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360:679–91.CrossRefPubMed
52.
Vidal L, Ben-Aharon I, Rizel S, et al. Bisphosphonates in the adjuvant setting of breast cancer therapy: effect on survival—a systematic review and meta-analysis. J Clin Oncol. 2012;30:Abstract 548.
53.
Ottewell PD et al. Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo. Clin Cancer Res. 2014;20:2922–32.CrossRefPubMedPubMedCentral
54.
Shepherd LE, Chapman JA, Ali SM, et al. Effect of osteoporosis in postmenopausal breast cancer patients randomized to adjuvant exemestane or anastrozole: NCIC CTG MA.27. J Clin Oncol. 2012;30:Abstract 501.
55.
Goss PE, Ingle JN, Pritchard KI, et al. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27–a randomized controlled phase III trial. J Clin Oncol. 2013;31:1398–404.CrossRefPubMedPubMedCentral
56.
Li L, Neaves WB. Normal stem cells and cancer stem cells: the niche matters. Cancer Res. 2006;66:4553–7.CrossRefPubMed
57.
Gnant M, Mlineritsch B, Stoeger H, et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol. 2015;26:313–20.CrossRefPubMed
Metadata
Title
Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence
Authors
Daniele Santini
Luciano Stumbo
Chiara Spoto
Loretta D’Onofrio
Francesco Pantano
Michele Iuliani
Marco fioramonti
Alice Zoccoli
Giulia Ribelli
Vladimir Virzì
Bruno Vincenzi
Giuseppe Tonini
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2015
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-015-0634-8

Other articles of this Issue 1/2015

Breast Cancer Research 1/2015 Go to the issue

Viewpoint

Tumor-induced inflammation alters neutrophil phenotype and disease progression

Research article

Mouse mammary stem cells express prognostic markers for triple-negative breast cancer

Review

Benefits and harms of mammography screening

Research article

Long non-coding RNA expression profiles predict metastasis in lymph node-negative breast cancer independently of traditional prognostic markers

Research article

Assessing breast cancer cell lines as tumour models by comparison of mRNA expression profiles

Research article

Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits